Zacks Investment Research downgraded shares of INSMED INC (INSM) from OUTPERFORM to NEUTRAL on August 03, 2012, with a target price of $4.00.
Insmed Pharmaceuticals is a development stage pharmaceutical company that is developing drugs to treat metabolic and endocrine diseases associated with insulin resistance. The company's first drug candidate, INS-1, is currently targeted towards the treatment of type 2 diabetes and polycystic ovary syndrome. The company is currently conducting multi-center phase II clinical trials for both indications. The company's objective is to establish a leading position in the treatment of metabolic and endocrine diseases.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on INSMED INC (INSM),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment